Janssen drops price of Imbruvica to secure NICE nod
It is looking likely that Janssen’s Imbruvica will be available to treat some people with chronic lymphocytic leukaemia (CLL) routinely on the NHS, after cost regulators issued draft guidelines endorsing its use.
Read More
